First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference
Zurich, October 27, 2015. Molecular Partners AG (ticker: MOLN) announced today that interim clinical data on MP0250 will be presented from the ongoing Phase I dose escalation study in solid tumors. Prof. Dr. Jordi Rodon, Hospital Vall d’Hebron Institute of Oncology, Barcelona and a principal investigator of this study, will present the most recent data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on November 07, 2015.
The corresponding abstract has been published on the AACR-NCI-EORTC webpage: LINK.
MP0250 is a multi-DARPin blocking both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) from binding to their receptors, thereby inhibiting tumor growth and tumor proliferation. MP0250 is the most advanced systemic DARPin of Molecular Partners.
The presentation of the interim clinical data represents a key milestone for Molecular Partners. The clinical trial of MP0250 is currently ongoing and is a key asset in the diverse proprietary oncology pipeline of the company.
About Molecular Partners AG
Molecular Partners is a public, clinical stage, biopharmaceutical company listed on the SIX Swiss Exchange (ticker symbol: MOLN) that is developing a new powerful class of therapies known as DARPins. DARPins are potent, specific and versatile small protein therapies which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to enable a multi-specific approach to treatment which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. Its most advanced product candidate is abicipar. The company has ongoing research and development partnerships with leading pharmaceutical companies including Allergan and Janssen and is backed by established biotech investors. For more information regarding Molecular Partners, go to: www.molecularpartners.com.
For further details please contact:
Dr. Christian Zahnd, CEO
Dr. Patrick Amstutz, COO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
Tel: +44 (0) 208 877 8400
This announcement is not an offer to sell, or a solicitation of an offer to purchase, any securities of Molecular Partners AG (the “Company”), nor shall it or any part of it form the basis of, or be relied on in connection with any contract or investment decision. This announcement is not for publication or distribution (directly or indirectly) in or to the United States, Canada, Australia, Japan or any other jurisdiction in which such distribution would be unlawful.
This announcement contains statements that are, or may be deemed to be, forward-looking statements. In some case, these forward-looking statements can be identified by the use of forward-looking terminology or subjective assessments, including the words “potential”, “expects”, “targets”, “designed”, “intends” or “plans” or comparable terminology or by discussions of plans, objectives, targets, goals, future events or intentions. These forward-looking statements include matters that are not historical facts or which may not otherwise be provable by reference to past events, and are based on assumptions. By their nature, forward- looking statements are subject to known and unknown risks and uncertainties because they relate to events and/or depend on circumstances that may or may not occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of the Company cannot be relied on as a guide to future performance.
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the Company nor any other person undertakes any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.